See more : Lenta International public joint-stock company (LENTY) Income Statement Analysis – Financial Results
Complete financial analysis of Entera Bio Ltd. (ENTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Entera Bio Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Catena AB (publ) (0GVS.L) Income Statement Analysis – Financial Results
- Bridgemarq Real Estate Services Inc. (BREUF) Income Statement Analysis – Financial Results
- Cera Sanitaryware Limited (CERA.BO) Income Statement Analysis – Financial Results
- Rectron Limited (2302.TW) Income Statement Analysis – Financial Results
- B.Grimm Power Public Company Limited (BGRIM.BK) Income Statement Analysis – Financial Results
Entera Bio Ltd. (ENTX)
About Entera Bio Ltd.
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 134.00K | 571.00K | 365.00K | 236.00K | 500.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 56.00K | 101.00K | 373.00K | 209.00K | 210.00K | 0.00 | 43.00K | 35.00K | 28.00K |
| Gross Profit | -56.00K | 33.00K | 198.00K | 156.00K | 26.00K | 500.00K | -43.00K | -35.00K | -28.00K |
| Gross Profit Ratio | 0.00% | 24.63% | 34.68% | 42.74% | 11.02% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 4.51M | 5.85M | 6.77M | 6.40M | 7.20M | 8.52M | 2.77M | 2.65M | 2.12M |
| General & Administrative | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.43M | 7.25M | 5.69M | 4.89M | 4.28M | 2.84M | 8.58M | 2.72M | 1.59M |
| Other Expenses | 0.00 | -51.00K | -46.00K | 1.24M | 743.00K | 523.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.86M | 13.05M | 12.42M | 11.29M | 11.48M | 11.36M | 11.34M | 5.37M | 3.70M |
| Cost & Expenses | 8.86M | 13.15M | 12.79M | 11.50M | 11.69M | 11.36M | 11.34M | 5.37M | 3.70M |
| Interest Income | 31.00K | 83.00K | 0.00 | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 29.00K | 28.00K | 84.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 56.00K | 64.00K | 53.00K | 63.00K | 238.00K | 54.00K | 43.00K | 35.00K | 28.00K |
| EBITDA | -8.80M | -12.87M | -12.16M | -11.11M | -11.35M | -10.81M | -11.05M | -5.33M | -3.67M |
| EBITDA Ratio | 0.00% | -9,714.18% | -2,130.30% | -3,050.14% | -4,752.54% | -2,161.40% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.89M | -13.02M | -12.22M | -11.13M | -11.45M | -10.86M | 11.34M | -5.37M | -3.70M |
| Operating Income Ratio | 0.00% | -9,714.18% | -2,139.58% | -3,050.14% | -4,853.39% | -2,172.20% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 31.00K | 134.00K | -29.00K | -28.00K | 659.00K | 557.00K | 146.00K | 4.17M | -581.00K |
| Income Before Tax | -8.86M | -12.93M | -12.25M | -9.96M | -10.80M | -10.30M | -11.20M | -1.20M | -4.28M |
| Income Before Tax Ratio | 0.00% | -9,652.24% | -2,144.66% | -2,729.59% | -4,574.15% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 29.00K | 137.00K | -59.00K | 20.00K | 84.00K | 557.00K | -146.00K | 0.00 | 0.00 |
| Net Income | -8.89M | -13.07M | -12.19M | -9.98M | -10.88M | -10.30M | -11.20M | -1.20M | -4.28M |
| Net Income Ratio | 0.00% | -9,754.48% | -2,134.33% | -2,735.07% | -4,609.75% | -2,060.80% | 0.00% | 0.00% | 0.00% |
| EPS | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.30 | -1.31 | -0.14 | -0.36 |
| EPS Diluted | -0.31 | -0.45 | -0.47 | -0.54 | -0.90 | -1.29 | -0.94 | -0.10 | -0.36 |
| Weighted Avg Shares Out | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.96M | 8.57M | 8.57M | 11.90M |
| Weighted Avg Shares Out (Dil) | 29.01M | 28.81M | 26.13M | 18.42M | 12.15M | 7.98M | 11.90M | 11.90M | 11.90M |
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.
Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data
Entera Bio Ltd (NASDAQ: ENTX) has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis. The Phase 2 Dose-Ranging study showed clinically significant changes in increases in...
Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session
Increases in lumbar spine, femoral neck and total hip BMD demonstrated with EB613
Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting
‒ Second of Two Presentations to be Delivered by Entera ‒
Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced it will host its annual shareholders meeting on Monday, October 4, 2021.
Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference
BOSTON and JERUSALEM, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the Company's CEO Spiros Jamas will present at the H.C. Wainwright 23rd Annual...
New Strong Sell Stocks for August 19th
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript
Entera Bio Ltd. (ENTX) CEO Spiros Jamas on Q2 2021 Results - Earnings Call Transcript
Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates
‒ Phase 2 EB613 Clinical Trial in Osteoporosi s Achieves 6-month Bone Mineral Density Endpoint; Primary and Key Secondary Endpoints Met ‒
Entera Bio to Report Business and Financial Results for the Quarter ended June 30, 2021, on August 16, 2021
BOSTON and JERUSALEM, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and financial results for the quarter ended June 30, 2021,...
Source: https://incomestatements.info
Category: Stock Reports